

Youngchul Kim

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3499986/publications.pdf>

Version: 2024-02-01

16
papers

241
citations

1307594

7
h-index

996975

15
g-index

16
all docs

16
docs citations

16
times ranked

573
citing authors

#	ARTICLE	IF	CITATIONS
1	A Randomized Clinical Trial of Precision Prevention Materials Incorporating <i>MC1R</i> Genetic Risk to Improve Skin Cancer Prevention Activities Among Hispanics. <i>Cancer Research Communications</i> , 2022, 2, 28-38.	1.7	9
2	Quantification of T- and B-cell Immune Receptor Distribution Diversity Characterizes Immune Cell Infiltration and Lymphocyte Heterogeneity in Clear Cell Renal Cell Carcinoma. <i>Cancer Research</i> , 2022, 82, 929-942.	0.9	13
3	Assessment of melanoma precision prevention materials incorporating <i>MC1R</i> genetic risk information. <i>Translational Behavioral Medicine</i> , 2022, 12, 683-687.	2.4	3
4	Retention and Evaluation of Precision and Generic Prevention Materials for Melanoma: A Qualitative Study Comparing Young Adults and Adults. <i>Cancer Prevention Research</i> , 2022, 15, 533-542.	1.5	1
5	Proteogenomic, Epigenetic, and Clinical Implications of Recurrent Aberrant Splice Variants in Clear Cell Renal Cell Carcinoma. <i>European Urology</i> , 2022, 82, 354-362.	1.9	13
6	Assessment of skin cancer precision prevention materials among Hispanics in Florida and Puerto Rico. <i>Patient Education and Counseling</i> , 2022, 105, 3143-3150.	2.2	1
7	Aberrant Epidermal Growth Factor Receptor RNA Splice Products Are Among the Most Frequent Somatic Alterations in Clear Cell Renal Cell Carcinoma and Are Associated with a Poor Response to Immunotherapy. <i>European Urology Focus</i> , 2021, 7, 373-380.	3.1	4
8	PDXGEM: patient-derived tumor xenograft-based gene expression model for predicting clinical response to anticancer therapy in cancer patients. <i>BMC Bioinformatics</i> , 2020, 21, 288.	2.6	13
9	Investigating multi-radiomic models for enhancing prediction power of cervical cancer treatment outcomes. <i>Physica Medica</i> , 2018, 46, 180-188.	0.7	34
10	Impact of viral presence in tumor on gene expression in non-small cell lung cancer. <i>BMC Cancer</i> , 2018, 18, 843.	2.6	16
11	CONCORD biomarker prediction for novel drug introduction to different cancer types. <i>Oncotarget</i> , 2018, 9, 1091-1106.	1.8	5
12	Point success rate for patient therapeutic response prediction by continuous biomarker scores. <i>Statistical Methods in Medical Research</i> , 2016, 25, 1638-1647.	1.5	0
13	Retrospective Analysis of Survival Improvement by Molecular Biomarker-Based Personalized Chemotherapy for Recurrent Ovarian Cancer. <i>PLoS ONE</i> , 2014, 9, e86532.	2.5	13
14	Multi-Gene Expression Predictors of Single Drug Responses to Adjuvant Chemotherapy in Ovarian Carcinoma: Predicting Platinum Resistance. <i>PLoS ONE</i> , 2012, 7, e30550.	2.5	95
15	A Systematic Evaluation of Multi-Gene Predictors for the Pathological Response of Breast Cancer Patients to Chemotherapy. <i>PLoS ONE</i> , 2012, 7, e49529.	2.5	20
16	Double error shrinkage method for identifying protein binding sites observed by tiling arrays with limited replication. <i>Bioinformatics</i> , 2009, 25, 2486-2491.	4.1	1